In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

More thyroid cancers were detected soon after starting a GLP-1 receptor agonist than other diabetes drugs, a secondary ...

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

The first study examines TNF-a levels in patients receiving the GLP-1 agonist Wegovy ® or Ozempic ® who show signs of increased inflammation associated with sarcopenia, which is the progressive loss ...

Learn how diabetes medications could revolutionize stroke prevention and enhance heart and brain health with breakthrough ...

(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...

Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP ...